A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.
Identifieur interne : 000004 ( PubMed/Curation ); précédent : 000003; suivant : 000005A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.
Auteurs : Andrew Smith [États-Unis] ; Laura Rodriguez [États-Unis] ; Maya El Ghouayel [États-Unis] ; Aitor Nogales [États-Unis] ; Jeffrey M. Chamberlain [États-Unis] ; Katherine Sortino [États-Unis] ; Emma Reilly [États-Unis] ; Changyong Feng [États-Unis] ; David J. Topham [États-Unis] ; Luis Martínez-Sobrido [États-Unis] ; Stephen Dewhurst [États-Unis]Source :
- Journal of virology [ 1098-5514 ] ; 2020.
Abstract
Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based, contains either the internal genes of the 1960 A/Ann Arbor/6/60 or the 1957 A/Leningrad/17/57 H2N2 viruses (i.e., they diverge considerably from currently circulating strains). We previously showed that introduction of the temperature-sensitive (ts) residue signature of the AA/60 MDV into a 2009 pandemic A/California/04/09 H1N1 virus (Cal/09) results in only 10-fold in vivo attenuation in mice. We have previously shown that the ts residue signature of the Russian A/Leningrad/17/57 H2N2 LAIV (Len LAIV) more robustly attenuates the prototypical A/Puerto Rico/8/1934 (PR8) H1N1 virus. In this work, we therefore introduced the ts signature from Len LAIV into Cal/09. This new Cal/09 LAIV is ts in vitro, highly attenuated (att) in mice, and protects from a lethal homologous challenge. In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mice, it provided enhanced protection against a wild-type Cal/09 challenge relative to a PR8 LAIV with the same attenuating mutations. These findings suggest it may be possible to improve the efficacy of LAIVs by better matching the sequence of the MDV to currently circulating strains.IMPORTANCE Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV.
DOI: 10.1128/JVI.01065-19
PubMed: 31748399
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000004
Links to Exploration step
pubmed:31748399Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.</title>
<author><name sortKey="Smith, Andrew" sort="Smith, Andrew" uniqKey="Smith A" first="Andrew" last="Smith">Andrew Smith</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rodriguez, Laura" sort="Rodriguez, Laura" uniqKey="Rodriguez L" first="Laura" last="Rodriguez">Laura Rodriguez</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="El Ghouayel, Maya" sort="El Ghouayel, Maya" uniqKey="El Ghouayel M" first="Maya" last="El Ghouayel">Maya El Ghouayel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nogales, Aitor" sort="Nogales, Aitor" uniqKey="Nogales A" first="Aitor" last="Nogales">Aitor Nogales</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chamberlain, Jeffrey M" sort="Chamberlain, Jeffrey M" uniqKey="Chamberlain J" first="Jeffrey M" last="Chamberlain">Jeffrey M. Chamberlain</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sortino, Katherine" sort="Sortino, Katherine" uniqKey="Sortino K" first="Katherine" last="Sortino">Katherine Sortino</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Reilly, Emma" sort="Reilly, Emma" uniqKey="Reilly E" first="Emma" last="Reilly">Emma Reilly</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, Changyong" sort="Feng, Changyong" uniqKey="Feng C" first="Changyong" last="Feng">Changyong Feng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Topham, David J" sort="Topham, David J" uniqKey="Topham D" first="David J" last="Topham">David J. Topham</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Martinez Sobrido, Luis" sort="Martinez Sobrido, Luis" uniqKey="Martinez Sobrido L" first="Luis" last="Martínez-Sobrido">Luis Martínez-Sobrido</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dewhurst, Stephen" sort="Dewhurst, Stephen" uniqKey="Dewhurst S" first="Stephen" last="Dewhurst">Stephen Dewhurst</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA Stephen_Dewhurst@urmc.rochester.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31748399</idno>
<idno type="pmid">31748399</idno>
<idno type="doi">10.1128/JVI.01065-19</idno>
<idno type="wicri:Area/PubMed/Corpus">000004</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000004</idno>
<idno type="wicri:Area/PubMed/Curation">000004</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000004</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.</title>
<author><name sortKey="Smith, Andrew" sort="Smith, Andrew" uniqKey="Smith A" first="Andrew" last="Smith">Andrew Smith</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rodriguez, Laura" sort="Rodriguez, Laura" uniqKey="Rodriguez L" first="Laura" last="Rodriguez">Laura Rodriguez</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="El Ghouayel, Maya" sort="El Ghouayel, Maya" uniqKey="El Ghouayel M" first="Maya" last="El Ghouayel">Maya El Ghouayel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nogales, Aitor" sort="Nogales, Aitor" uniqKey="Nogales A" first="Aitor" last="Nogales">Aitor Nogales</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chamberlain, Jeffrey M" sort="Chamberlain, Jeffrey M" uniqKey="Chamberlain J" first="Jeffrey M" last="Chamberlain">Jeffrey M. Chamberlain</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sortino, Katherine" sort="Sortino, Katherine" uniqKey="Sortino K" first="Katherine" last="Sortino">Katherine Sortino</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Reilly, Emma" sort="Reilly, Emma" uniqKey="Reilly E" first="Emma" last="Reilly">Emma Reilly</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, Changyong" sort="Feng, Changyong" uniqKey="Feng C" first="Changyong" last="Feng">Changyong Feng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Topham, David J" sort="Topham, David J" uniqKey="Topham D" first="David J" last="Topham">David J. Topham</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Martinez Sobrido, Luis" sort="Martinez Sobrido, Luis" uniqKey="Martinez Sobrido L" first="Luis" last="Martínez-Sobrido">Luis Martínez-Sobrido</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dewhurst, Stephen" sort="Dewhurst, Stephen" uniqKey="Dewhurst S" first="Stephen" last="Dewhurst">Stephen Dewhurst</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA Stephen_Dewhurst@urmc.rochester.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Rochester, Rochester, New York</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based, contains either the internal genes of the 1960 A/Ann Arbor/6/60 or the 1957 A/Leningrad/17/57 H2N2 viruses (i.e., they diverge considerably from currently circulating strains). We previously showed that introduction of the temperature-sensitive (<i>ts</i>
) residue signature of the AA/60 MDV into a 2009 pandemic A/California/04/09 H1N1 virus (Cal/09) results in only 10-fold <i>in vivo</i>
attenuation in mice. We have previously shown that the <i>ts</i>
residue signature of the Russian A/Leningrad/17/57 H2N2 LAIV (Len LAIV) more robustly attenuates the prototypical A/Puerto Rico/8/1934 (PR8) H1N1 virus. In this work, we therefore introduced the <i>ts</i>
signature from Len LAIV into Cal/09. This new Cal/09 LAIV is <i>ts in vitro</i>
, highly attenuated (<i>att</i>
) in mice, and protects from a lethal homologous challenge. In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mice, it provided enhanced protection against a wild-type Cal/09 challenge relative to a PR8 LAIV with the same attenuating mutations. These findings suggest it may be possible to improve the efficacy of LAIVs by better matching the sequence of the MDV to currently circulating strains.<b>IMPORTANCE</b>
Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">31748399</PMID>
<DateRevised><Year>2020</Year>
<Month>02</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>94</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>Jan</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e01065-19</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01065-19</ELocationID>
<Abstract><AbstractText>Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based, contains either the internal genes of the 1960 A/Ann Arbor/6/60 or the 1957 A/Leningrad/17/57 H2N2 viruses (i.e., they diverge considerably from currently circulating strains). We previously showed that introduction of the temperature-sensitive (<i>ts</i>
) residue signature of the AA/60 MDV into a 2009 pandemic A/California/04/09 H1N1 virus (Cal/09) results in only 10-fold <i>in vivo</i>
attenuation in mice. We have previously shown that the <i>ts</i>
residue signature of the Russian A/Leningrad/17/57 H2N2 LAIV (Len LAIV) more robustly attenuates the prototypical A/Puerto Rico/8/1934 (PR8) H1N1 virus. In this work, we therefore introduced the <i>ts</i>
signature from Len LAIV into Cal/09. This new Cal/09 LAIV is <i>ts in vitro</i>
, highly attenuated (<i>att</i>
) in mice, and protects from a lethal homologous challenge. In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mice, it provided enhanced protection against a wild-type Cal/09 challenge relative to a PR8 LAIV with the same attenuating mutations. These findings suggest it may be possible to improve the efficacy of LAIVs by better matching the sequence of the MDV to currently circulating strains.<b>IMPORTANCE</b>
Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV.</AbstractText>
<CopyrightInformation>Copyright © 2020 Smith et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Medical Scientist Training Program, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rodriguez</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>El Ghouayel</LastName>
<ForeName>Maya</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nogales</LastName>
<ForeName>Aitor</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chamberlain</LastName>
<ForeName>Jeffrey M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sortino</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Reilly</LastName>
<ForeName>Emma</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Changyong</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Topham</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-9435-8673</Identifier>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martínez-Sobrido</LastName>
<ForeName>Luis</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dewhurst</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-7729-7920</Identifier>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA Stephen_Dewhurst@urmc.rochester.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>01</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IIV</Keyword>
<Keyword MajorTopicYN="N">LAIV</Keyword>
<Keyword MajorTopicYN="N">MDV</Keyword>
<Keyword MajorTopicYN="N">heterologous immunity and protection</Keyword>
<Keyword MajorTopicYN="N">inactivated influenza vaccine</Keyword>
<Keyword MajorTopicYN="N">influenza</Keyword>
<Keyword MajorTopicYN="N">live attenuated influenza vaccine</Keyword>
<Keyword MajorTopicYN="N">master donor virus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>06</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>11</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31748399</ArticleId>
<ArticleId IdType="pii">JVI.01065-19</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.01065-19</ArticleId>
<ArticleId IdType="pmc">PMC6997774</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2006 Dec;80(23):11756-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16971435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2011 Sep 15;204(6):845-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21846636</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Rep. 2016 Aug 16;16(7):1800-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27498869</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2017 Jan 31;91(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27928017</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Microbiol. 2017 Jun 05;2:17088</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28581455</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2000 Mar;181(3):1133-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10720541</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2007 Jan 15;25(5):846-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17074423</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2012 May 21;30(24):3691-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22449422</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2011 Jan;85(1):448-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20980523</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20798667</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2017 Aug 10;91(17):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28637750</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2010 May;84(9):4587-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20181702</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Scand J Immunol. 2004 Jan;59(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14723616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2018 Jul 2;218(3):347-354</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29506129</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Leukoc Biol. 2014 Feb;95(2):215-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24006506</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2011 May 31;108(22):9178-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21562214</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2017 Apr;504:96-106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28167384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bull World Health Organ. 1996;74(1):77-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8653819</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 2014 Aug;410:60-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24709389</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2011 Jan;85(1):456-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20962084</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2008 Oct 25;380(2):304-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18768193</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2012 Sep 27;489(7417):526-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22982990</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Aug 3;35(34):4374-4381</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28709557</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2018 Mar;516:76-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29331866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Rep. 2018 Sep 25;24(13):3374-3382.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30257199</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2019 Oct 10;11(10):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31658679</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Mar;89(6):3421-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25552727</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Vis Exp. 2010 Aug 03;(42):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20729804</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Genet Evol. 2018 Oct;64:95-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29929009</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2011 Apr 10;412(2):297-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21315402</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2013 Oct;19(10):1305-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24056771</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2018 Apr 3;14(4):941-946</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29252117</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2010 Oct;10(10):699-711</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20883966</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2007 Sep;81(17):9238-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17596317</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2016 Sep 06;6:32973</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27596047</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2015 Mar;14(3):167-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25722244</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Immunol. 2017 Jun 2;2(12):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28783656</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2018 Jan 19;359(6373):290-296</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29348231</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2014 Sep;88(18):10525-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24965472</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2008 Jul;15(7):1042-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18448618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Immunol. 2017 Jan 6;2(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28783666</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Dec 16;90(5):2702-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26676793</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S82-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15577936</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2000 Apr;74(8):3486-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10729122</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2014 Aug 1;193(3):1324-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24958904</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JCI Insight. 2016 Jul 7;1(10):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27468427</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pediatr. 2000 Feb;136(2):168-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10657821</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2016 Jun 24;90(14):6291-6302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27122587</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell. 1986 Mar 28;44(6):959-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2420472</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jan;78(2):995-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14694130</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2016 Jan 27;34(5):622-629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26724200</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Microbiol. 2012 Jun;20(6):275-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22520511</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000004 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000004 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:31748399 |texte= A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31748399" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |